How a gum bacterium weakens the mouth's antiviral defenses

Regulation and Manipulation of Oral Type III Interferon Responses by Porphyromonas gingivalis

NIH-funded research Research Inst Nationwide Children's Hosp · NIH-11258942

This research looks at whether the common gum bacterium Porphyromonas gingivalis weakens antiviral signals in the mouth lining, potentially increasing risk of oral viral infections.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionResearch Inst Nationwide Children's Hosp NIH-funded
Lab location1 site (Columbus, United States)
Project IDNIH-11258942 on NIH RePORTER

What this research studies

This project focuses on Porphyromonas gingivalis, a bacterium linked to gum disease, and how it affects Type III interferons (IFN-λ) that protect the oral lining. Researchers will work with oral epithelial cells, bacterial exposures, viral stimulants, and immune cell tests to see if the bacterium blocks antiviral signaling and changes neutrophil responses. They will also examine whether suppressing IFN-λ makes it harder to clear viruses and helps the bacterium persist in the mouth. Findings aim to point toward ways to boost oral antiviral defenses or limit harmful bacterial effects.

Who could benefit from this research

Good fit: People with periodontal (gum) disease, frequent oral viral infections, or ongoing oral inflammation would be the most likely candidates to participate or benefit.

Not a fit: People without gum disease or no history of oral viral problems would be unlikely to receive direct benefit from this laboratory-focused research.

Why it matters

Potential benefit: If successful, this work could point to new ways to prevent or treat oral viral infections or gum disease by restoring IFN-λ signaling or targeting the bacterium.

How similar studies have performed: Previous laboratory studies have shown IFN-λ protects oral mucosa and that bacteria can alter interferon responses, but applying these findings specifically to Porphyromonas gingivalis's suppression of IFN-λ is a relatively new approach.

Where this research is happening

Columbus, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Bacterial Infections
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.